PPAR-β/δ Is Required for Metabolic and Inflammatory Adaptation to Glucose Restriction in T98G Glioblastoma Cells

Background: Glioblastoma (GBM) shows marked metabolic plasticity and resistance to conventional therapies, which has motivated the search for adjunctive metabolic strategies. Medium-chain fatty acids (MCFAs) are candidate metabolic modulators, but the mechanisms underlying their effects in GBM are poorly understood. This study investigated the role of peroxisome proliferator-activated receptor beta/delta (PPAR-β/δ, hereafter PPAR-β) in the metabolic and inflammatory responses of GBM cells to MCFAs under different glucose conditions. Methods: T98G glioblastoma cells were cultured in normal-glucose (NG, 4.5 g/L) or low-glucose (LG, 1 g/L) medium and treated for 72 h with octanoic acid (C8:0, C8), decanoic acid (C10:0, C10) or the PPAR-β agonist GW501516. Metabolic activity (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, MTT), reactive oxygen species (ROS) and superoxide production, expression of ACADM, OGDH, SLC16A1, IDH1, PTEN and BCL2 by quantitative polymerase chain reaction (qPCR), and secretion of a seven-analyte cytokine panel were evaluated. The contribution of PPAR-β was assessed by small interfering RNA (siRNA)-mediated silencing, which reduced PPARD mRNA by approximately 86%. Results: C8 and C10 increased metabolic activity under both glucose conditions, and glucose restriction reduced ROS and superoxide production in treated cells. In PPAR-β-silenced cells, glucose restriction almost abolished ACADM and SLC16A1 expression (both p < 0.0001 in untreated cells) and markedly increased OGDH expression (up to approximately 600-fold), indicating that PPAR-β is required to sustain the expression of genes involved in medium-chain fatty acid oxidation and monocarboxylate transport when glucose is limiting. Under low glucose, PPAR-β silencing reduced PTEN and BCL2 expression to approximately 1.5–1.8% of the level in non-transfected cells (both p < 0.0001), whereas under normal glucose it increased BCL2 (up to 10.8-fold, p = 0.0015) and increased PTEN in GW501516-treated cells (p = 0.0005). Interleukin (IL)-8 was the only analyte of the cytokine panel that could be quantified reliably; it was not significantly changed by glucose restriction alone but was higher in PPAR-β-silenced than in non-transfected cells under low glucose (untreated, p = 0.0099; C10, p = 0.0021). Conclusions: PPAR-β links glucose availability to metabolic reprogramming, to tumour-suppressor and survival gene expression, and to IL-8 secretion in GBM cells. These findings identify PPAR-β as a candidate therapeutic target and support the further evaluation of MCFAs as adjunctive metabolic interventions in glioblastoma.

Authors

Institutions

Publication Details

Journal
Biomedicines
Published
2026-11-13
DOI
https://doi.org/10.3390/biomedicines14112620
Primary Topic
Peroxisome Proliferator-Activated Receptors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

PPAR-β/δ Is Required for Metabolic and Inflammatory Adaptation to Glucose Restriction in T98G Glioblastoma Cells

Luz Norela Correa, Mónica Losada-Barragán, Karina Vargas-Sánchez, Adriana Puerta et al.
2 links
Biomedicines
Peroxisome Proliferator-Activated Receptors
article

PPAR-β/δ Is Required for Metabolic and Inflammatory Adaptation to Glucose Restriction in T98G Glioblastoma Cells

Luz Norela Correa, Mónica Losada-Barragán, Karina Vargas-Sánchez, Adriana Puerta, Andres Cuellar-Quimbaya, Laura Vargas, Katherine García
article en

Abstract

Background: Glioblastoma (GBM) shows marked metabolic plasticity and resistance to conventional therapies, which has motivated the search for adjunctive metabolic strategies. Medium-chain fatty acids (MCFAs) are candidate metabolic modulators, but the mechanisms underlying their effects in GBM are poorly understood. This study investigated the role of peroxisome proliferator-activated receptor beta/delta (PPAR-β/δ, hereafter PPAR-β) in the metabolic and inflammatory responses of GBM cells to MCFAs under different glucose conditions. Methods: T98G glioblastoma cells were cultured in normal-glucose (NG, 4.5 g/L) or low-glucose (LG, 1 g/L) medium and treated for 72 h with octanoic acid (C8:0, C8), decanoic acid (C10:0, C10) or the PPAR-β agonist GW501516. Metabolic activity (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, MTT), reactive oxygen species (ROS) and superoxide production, expression of ACADM, OGDH, SLC16A1, IDH1, PTEN and BCL2 by quantitative polymerase chain reaction (qPCR), and secretion of a seven-analyte cytokine panel were evaluated. The contribution of PPAR-β was assessed by small interfering RNA (siRNA)-mediated silencing, which reduced PPARD mRNA by approximately 86%. Results: C8 and C10 increased metabolic activity under both glucose conditions, and glucose restriction reduced ROS and superoxide production in treated cells. In PPAR-β-silenced cells, glucose restriction almost abolished ACADM and SLC16A1 expression (both p < 0.0001 in untreated cells) and markedly increased OGDH expression (up to approximately 600-fold), indicating that PPAR-β is required to sustain the expression of genes involved in medium-chain fatty acid oxidation and monocarboxylate transport when glucose is limiting. Under low glucose, PPAR-β silencing reduced PTEN and BCL2 expression to approximately 1.5–1.8% of the level in non-transfected cells (both p < 0.0001), whereas under normal glucose it increased BCL2 (up to 10.8-fold, p = 0.0015) and increased PTEN in GW501516-treated cells (p = 0.0005). Interleukin (IL)-8 was the only analyte of the cytokine panel that could be quantified reliably; it was not significantly changed by glucose restriction alone but was higher in PPAR-β-silenced than in non-transfected cells under low glucose (untreated, p = 0.0099; C10, p = 0.0021). Conclusions: PPAR-β links glucose availability to metabolic reprogramming, to tumour-suppressor and survival gene expression, and to IL-8 secretion in GBM cells. These findings identify PPAR-β as a candidate therapeutic target and support the further evaluation of MCFAs as adjunctive metabolic interventions in glioblastoma.

BiomedicinesVol. 14(11)
Universidad de Los Andes (CO), Universidad Antonio Nariño (CO)
Good health and well-being
Peroxisome Proliferator-Activated Receptors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon